Small fragments, big impact: discovering the 'shearosomes' that drive cancer's spreadA collaborative study reveals an unexpected way cancer spreads through the body – by shedding tiny, previously ...

Thousands of women with breast cancer could be spared unnecessary treatment, thanks to a simple test which can identify whether or not their cancer is likely to return – just two weeks after starting ...

Thousands of women who undergo radiotherapy for low-risk breast cancer could be spared some of the side effects of treatment after a study confirmed that more targeted treatments are just as effective ...

Late-effects of paediatric cancer treatmentNote: the ICR’s standard minimum entry requirement is a relevant undergraduate Honours degree (First or 2:1). Master in Epidemiology, Public Health, Data ...

Scientists have discovered clues which may explain why some treatments stop working for people with bowel cancer – causing around 16,800 deaths in the UK every year.

Thousands of patients with a common type of blood cancer could benefit from a new drug combination, while others could see their disease kept at bay for longer.

Dame Stella Rimington, who served as Chair of the Board of Trustees at The Institute of Cancer Research, London, from 1997 to 2005, died on 3 August 2025. Dame Stella took up the role of Chair ...

Dame Stella Rimington, former Chair of the ICR, dies aged 90Newsletter archive Search issue 51 - Spring 2025 Find out how our scientists are developing improved breast cancer tools that will help ...

ASCO 2025: AI test determines best prostate cancer treatment – which could save NHS moneyA new AI test can pick out which men with high-risk prostate cancer that has not spread will require ...

Blood cancer is an umbrella term for cancers affecting the blood, bone marrow or lymphatic system. Despite being a common cancer that can affect people of any age, it is often not very well understood ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned.

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...